Navigation Links
For Alzheimer's Disease, Surveyed Neurologists Identify a Therapy's Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
Date:4/29/2009

The Combination of Bapineuzumab and Donepezil Will Earn Decision Resources' Gold Standard Status for the Indication in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists identify a therapy's effect on cognitive decline as the attribute that most influences their prescribing decisions in mild to moderate Alzheimer's disease. As potential disease-modifying drugs, interviewed thought leaders indicate that Elan/Wyeth's bapineuzumab, Eli Lilly's solanezumab and semagacestat, Medivation/Pfizer's Dimebon and Baxter Healthcare's Gammagard all have advantages in this attribute over donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in the market.

The new report entitled Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status also finds that a therapy that prevents cognitive decline for a longer duration than donepezil for the treatment of mild to moderate Alzheimer's disease would earn a 50 percent patient share in the United States and a 45 percent patient share in Europe, according to surveyed U.S. and European neurologists.

In 2008, Decision Resources' proprietary clinical gold standard for mild to moderate Alzheimer's disease was donepezil. Based on available data and expert opinion, the combination of bapineuzumab and donepezil will earn gold standard status for the indication in 2012, following the approval of bapineuzumab in 2012.

"The bapineuzumab/donepezil combination, as a potential disease-modifying drug, may have competitive advantages in efficacy outcomes, including effect on cognitive decline," said Decision Resources Director Andrea Witt, Ph.D. "Thought leaders perceive this regimen as having the greatest potential efficacy in Alzheimer's disease and preliminary clinical trial results suggest that monoclonal antibodies such as bapineuzumab may have a greater impact than other emerging agents on all efficacy measures."

About the Report

Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. Renal function and heart disease, and more
3. Environmental stress probed in cardiovascular disease, diabetes
4. Study Links Coronary Disease, Colon Cancer
5. People with Schizophrenia More Likely to Die of Heart Disease, Reports the Harvard Mental Health Letter
6. To fight disease, animals, like plants, can tolerate parasites
7. Researchers Spot Link Between Heart Disease, Income
8. Children with sickle cell disease, silent strokes show some relief with blood transfusions
9. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
10. U.S. Deaths Down From Heart Disease, Stroke
11. Large Disparities in Kidney Testing Based on Disease, Gender and State, Quest Diagnostics Health Trends(TM) Report Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... MA (PRWEB) , ... April 21, 2017 , ... ... University professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. ... the relative proportion of young people involved in violence in the United States. ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, ... to communities throughout the greater Pittsburgh metropolitan region, is joining forces with the ... bicycles for differently-abled children. , Variety the Children’s Charity is a national organization ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... announced it’s been named Agency of Record (AOR) for Theravent, Inc. , ... eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand ...
(Date:4/21/2017)... British Columbia (PRWEB) , ... April 21, 2017 , ... ... at treating people who wish to overcome their mental health struggles. The Alive team ... Director Vic LeBouthillier says: “Our approach in dealing with a mental health struggle is ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... seeking candidates to serve on its Accreditation and Standards Committees to support ... mission is improving image quality and reducing patient radiation dose,” reports Eliot ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
(Date:4/18/2017)... DUBLIN , April 18, 2017 Research ... Devices Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at ... The report, Global Arthroscopy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology: